REG - Tristel PLC - Positive H1 Trading Update & Directorate Change

TristelAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260122:nRSV8531Pa&default-theme=true

RNS Number : 8531P  Tristel PLC  22 January 2026

TRISTEL plc

("Tristel" or the "Company")

 

Positive H1 Trading Update

& Directorate Change

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products,
announces a positive trading update for the six months ended 31 December 2025.
The board remains confident in delivering full year results in line with
market expectations and the Company's own performance targets.

 

H1 Financial Highlights

·    H1 revenues increased by 14% year-on-year

·    Gross Margins maintained at 81%

·    Adjusted EBITDA increased by 17%

·    EBITDA margins of 28%, comfortably ahead of the 'at least 25% target'

·    Continued progress in US with revenue growth in line with internal
forecasts

·    Tristel continues to be debt free and cash generative

·    Cash balances at 31 December 2025 were £13.3m

 

The above highlights are based on unaudited figures and the Company intends to
announce its interim results in early March.

 

Directorate Change

The Company also announces that Matt Sassone, Chief Executive Officer, has
confirmed to the Board his decision to resign to take up a worldwide President
role with a large US multinational, leading a significant global business.
Matt will actively continue in post until the end of the financial year and
has fully committed to continue leading the business through this period. The
Board has already commenced the process to appoint a new CEO and is confident
that there is sufficient management depth in the business to ensure that
trading will not be impacted during the transition.

 

Commenting Matt Sassone, Chief Executive Officer, said:

"This is undoubtably one of the hardest business decisions I have ever had to
make. The real strength of Tristel has never been one person, as the business
has been carefully built on leaders at every level. Our strategy for growth is
robust and remains unchanged, and the momentum we have is very real and can be
seen already in the strong H1 performance. I am confident that the investment
case of the business remains as compelling as ever.

 

"The opportunity I have to return to the US with my family, and to work in
such a senior role with a large US multinational, is one which resonates with
me on a personal level. It is with a very heavy heart that I will be leaving
Tristel and I remain confident in our ability to take full advantage of the
market opportunities, particularly in the US where there is clear evidence of
traction and scale-up potential.

 

"I would like to thank the Board and the wider Tristel team for their support
and hard work, and I would like to reassure investors that the business
remains in a very strong position. Any new CEO coming into this role will see
that this business has a well established platform to deliver significant
growth."

 

Bruno Holthof, Chair of the Tristel Board, commented: "On behalf of the
Company I would like to offer my thanks to Matt for his leadership, energy and
contribution to Tristel since joining us in 2024. He has made a real impact in
short period of time, and whilst we're sad to see him go, we respect his
decision and wish him every success. We are confident in the strength of the
leadership team and the wider organisation, and we remain confident that the
strong momentum of the business will continue. The Board has already commenced
the process of recruiting a new CEO, working carefully to find the right
leader to build on the strong foundations already in place."

 

 

 

 

For further information please contact:

 

 Tristel plc                                                                Via Walbrook PR
 Matt Sassone, Chief Executive Officer                                      https://investors.tristel.com/ (https://investors.tristel.com/)
 Anna Wasyl, Chief Financial Officer

 Walbrook PR Ltd                                                            Tel: 020 7933 8780 or tristel@walbrookpr.com
 Paul McManus / Lianne Applegarth / Anna Dunphy    Mob: 07980 541 893/ 07584 391 303/ 07876 741 001

 Cavendish Capital Markets Ltd                                              Tel: 020 7220 0500
 Geoff Nash / Callum Davidson / Trisyia Jamaludin (Corporate Finance)
 Sunila de Silva (ECM) / Louise Talbot (Sales)

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the EU Market Abuse
Regulation (596/2014) as it forms part of UK domestic law by virtue of the
European Union (Withdrawal) Act 2018, as amended. Upon the publication of
this announcement via a regulatory information service, this information is
considered to be in the public domain.

 

 

 

About Tristel plc

 

Tristel plc is a global infection prevention company focussed on the
manufacture and supply of products using its unique proprietary chlorine
dioxide (ClO(2)) chemistry. The Company is a market leader in manual
decontamination of medical devices, supplying hospitals under the Tristel
(https://tristel.com/tristel/) brand, and under the Cache
(https://tristel.com/cache/) brand provides products for sporicidal surface
disinfection, a more sustainable alternative to commonly used pre-wetted
plastic wipes.

 

Tristel's head office and manufacturing facility is located in Snailwell, near
Cambridge, and operates globally employing approximately 270 people across 16
subsidiaries selling into 40+ countries. The Company targets delivering
double-digit revenue growth annually, an adjusted EBITDA margin of at least
25% and a continuing progressive year-on-year growth in dividends, underpinned
by robust cash generation.

 

The Company has been listed on the London Stock Exchange's AIM market since
2005 (AIM: TSTL).

 

For more information about Tristel's product range please visit:
https://tristel.com (https://tristel.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCPPUWWGUPQGMG



            Copyright 2019 Regulatory News Service, all rights reserved